Arbutus Biopharma Corp Proceeds from Warrant Exercises
Arbutus Biopharma Corp (ABUS) reported Proceeds from Warrant Exercises of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2019-03-07
CAD
| Period end | Proceeds from Warrant Exercises 11 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|
| 2012-12-31 | 631.87K CAD 20-F · filed 2013-03-27 | 631.87K CAD 20-F · filed 2013-03-27 |
USD
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 3 month as first filed | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month | Proceeds from Warrant Exercises 12 month as first filed |
|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 10-K · filed 2019-03-07 | ||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-04 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $353.00K 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $353.00K 10-Q · filed 2018-11-07 | $353.00K derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | $353.00K 10-Q · filed 2018-08-03 | $353.00K derived: sum of 3 quarters · filed 2018-08-03 | $353.00K derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | $353.00K 10-Q · filed 2018-05-04 | $353.00K derived: sum of 2 quarters · filed 2018-05-04 | $353.00K derived: sum of 3 quarters · filed 2018-05-04 | $798.00K derived: sum of 4 quarters · filed 2018-05-04 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $445.00K derived: sum of 3 quarters · filed 2018-03-16 | $445.00K 10-K · filed 2018-03-16 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-02 | $445.00K derived: sum of 2 quarters · filed 2017-11-02 | $445.00K 10-Q · filed 2017-11-02 | $444.00K derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-06-30 | $445.00K 10-Q · filed 2017-08-03 | $445.00K 10-Q · filed 2017-08-03 | $444.00K derived: sum of 3 quarters · filed 2018-03-16 | $444.00K derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | -$1.00K derived: sum of 2 quarters · filed 2018-03-16 | -$1.00K derived: sum of 3 quarters · filed 2018-03-16 | $18.00K derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2015-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$1.00K derived: sum of 2 quarters · filed 2018-03-16 | $18.00K derived: sum of 3 quarters · filed 2018-03-16 | $42.00K 10-K · filed 2018-03-16 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | $19.00K derived: sum of 2 quarters · filed 2016-11-03 | $43.00K 10-Q · filed 2016-11-03 | $237.00K derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-06-30 | $19.00K 10-Q · filed 2016-08-04 | $44.00K 10-Q · filed 2016-08-04 | $237.00K derived: sum of 3 quarters · filed 2017-03-22 | $653.00K derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-03-31 | $25.00K 10-Q · filed 2016-05-04 | $218.00K derived: sum of 2 quarters · filed 2017-03-22 | $634.00K derived: sum of 3 quarters · filed 2017-03-22 | $720.00K derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2014-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $609.00K derived: sum of 2 quarters · filed 2017-03-22 | $695.00K derived: sum of 3 quarters · filed 2017-03-22 | $1.58M 10-K · filed 2017-03-22 | ||
| 2014-09-30 | $416.00K 10-Q · filed 2015-11-05 | $502.00K derived: sum of 2 quarters · filed 2015-11-05 | $1.39M 10-Q · filed 2015-11-05 | $1.51M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-06-30 | $86.00K 10-Q · filed 2015-08-07 | $974.00K 10-Q · filed 2015-08-07 | $1.09M derived: sum of 3 quarters · filed 2016-03-09 | $1.15M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-03-31 | $888.00K 10-Q · filed 2015-05-06 | $1.01M derived: sum of 2 quarters · filed 2016-03-09 | $1.06M derived: sum of 3 quarters · filed 2016-03-09 | $1.11M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2013-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $172.00K derived: sum of 2 quarters · filed 2016-03-09 | $226.00K derived: sum of 3 quarters · filed 2016-03-09 | $289.00K 10-K · filed 2016-03-09 | $288.82K 6-K · filed 2014-03-06 | |
| 2013-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $108.00K derived: sum of 2 quarters · filed 2014-11-07 | $171.00K 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | $54.00K 10-Q · filed 2014-11-07 | $61.00K 10-Q · filed 2014-08-14 | $117.00K 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | $56.00K 10-Q · filed 2014-05-14 | |||||
| 2012-12-31 | $632.00K 10-K · filed 2015-03-13 | $632.28K 6-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |